Goldman Sachs Upgrades Abbott Labs (ABT) to Buy

Goldman Sachs analyst Issac Ro upgraded Abbott Labs (NYSE: ABT) from Neutral to Buy with a price target of $81.00 (from $78.00).

The analyst favors the company growth among peers, likes the disconnect between an underappreciated consensus expectation and his believes the company will accrue a favorable mix shift, the potential upside in the valuation, more favorable outlook for EPD/Nutritionals than consensus expects and share gains in Diagnostics following recent checks.

For an analyst ratings summary and ratings history on Abbott Labs click here. For more ratings news on Abbott Labs click here.

Shares of Abbott Labs closed at $74.30 yesterday.

You May Also Be Interested In

• Keurig Dr Pepper (KDP) PT Raised to $39 at Jefferies
• Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
• HSBC Upgrades UPS (UPS) to Buy, 'Back to earnings growth'